Engineering the perfect (bacterial) cancer therapy
Open accessThe DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Abstract
Bacterial therapies possess many unique mechanisms for treating cancer that are unachievable with standard methods. Bacteria can specifically target tumours, actively penetrate tissue, are easily detected and can controllably induce cytotoxicity. Over the past decade, Salmonella, Clostridium and other genera have been shown to control tumour growth and promote survival in animal models. In this Innovation article I propose that synthetic biology techniques can be used to solve many of the key challenges that are associated with bacterial therapies, such as toxicity, stability and efficiency, and can be used to tune their beneficial features, allowing the engineering of 'perfect' cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in certain cases, injection of intratumoral bacteria or their antigens may conversely provide immunostimulatory effects, as demonstrated by Coley’s toxins and recent developments in bacterial cancer therapy (5, 105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
In the citing paper
“BCT is re-gaining attention through synthetic biology techniques that programmatically limit systemic toxicities while enhancing regional antitumor immunity (105, 106).”
From The microbiome and human cancer (2021) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guzman, L. M., Belin, D., Carson, M. J., & Beckwith, J. (1995) · Journal of Bacteriology · doi:10.1128/jb.177.14.4121-4130.1995 · Cited by 4,935
(1989) · PubMed · Cited by 3,343
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805 · cited 1×
“Many treatments, including chemotherapy and radiation, are toxic to normal tissue and cannot completely destroy all cancer cell”
BackgroundTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Automated design of synthetic ribosome binding sites to control protein expression
Salis, H. M., Mirsky, E. A., & Voigt, C. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1568 · Cited by 1,844
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“This containment is one possible reason that attenuated Salmonella had limited success in reducing tumour growth in human trial”
BackgroundCombination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563 · cited 1×
“For propulsion and sensing, bacteria have flagella that enable tissue penetratio”
BackgroundCombinatorial engineering of intergenic regions in operons tunes expression of multiple genes
Pfleger, B. F., Pitera, D. J., Smolke, C. D., & Keasling, J. D. (2006) · Nature Biotechnology · doi:10.1038/nbt1226 · Cited by 536 · cited 1×
“, including gene copy number, promoter strength, optimized codons, bacterial metabolism, mRNA secondary structur”
Background
Cited by
Items 501–600 of 905
Zhong, D., Xu, X., Li, Y., Wu, H., Zhang, Z., Yang, J., Zhang, H., Gong, Q., Luo, K., & Gu, Z. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100950 · Cited by 14
Therapeutic Potential of Bacteria against Solid Tumors
Hatzikirou, H., Alfonso, J. C. L., Leschner, S., Weiß, S., & Meyer‐Hermann, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1621 · Cited by 15
Advances in synthetic biology-based drug delivery systems for disease treatment
Li, Y., Wang, Y., Luo, Y.-G., Yang, H., Ren, J., & Xiao, L. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109576 · Cited by 17
Challenges and Opportunities of Gene Therapy in Cancer
Mittal, M., Kumari, A., Paul, B., Varshney, A., Bhavya, B., Saini, A., Verma, C., & Mani, I. (2024) · OBM Genetics · doi:10.21926/obm.genet.2401219 · Cited by 14
Engineering Microorganisms for Cancer Immunotherapy
Liu, D., Yu, L., Rong, H., Liu, L., & Yin, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304649 · Cited by 14
Anti-tumor activity of an αPD-L1-PE38 immunotoxin delivered by engineered Nissle 1917
Li, X., Wang, Y., Wang, Y., Xie, H., Gong, R., Wu, X., Chen, J., Sun, C., & Gu, Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139537 · Cited by 17
Liu, Z., Lei, L., Zhang, Z., Du, M., & Chen, Z. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101620 · Cited by 20
“Despite the advances made, achieving specific temporal and spatial control of protein expression in bacteria remains a challenge [41,42].”
Production and Characterization of Motile and Chemotactic Bacterial Minicells
Ni, B., Colin, R., & Sourjik, V. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00012 · Cited by 15
Takahashi, M., Sukowati, E. W., Nomura, S., Kato, A., Mizuseki, K., Watanabe, Y., & Mukai, H. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2122477 · Cited by 14
The Use of Bacteria in Cancer Treatment: A Review from the Perspective of Cellular Microbiology
Mills, H., Acquah, R., Tang, N., Cheung, L., Klenk, S., Glassen, R., Pirson, M. A., Albert, A., Hoang, D. T., & Van, T. (2022) · Emergency Medicine International · doi:10.1155/2022/8127137 · Cited by 15
“Bacteria with the capability of destroying tumors consume supplements required by the tumor for its growth [8], such that in some cases anaerobic bacteria end up multiplying in deoxygenated tumors [9].”
BackgroundRetractedMicrobiota in a long survival discourse with the human host
Ayariga, J. A., Ibrahim, I., Gildea, L., Abugri, J., & Villafañe, R. (2022) · Archives of Microbiology · doi:10.1007/s00203-022-03342-6 · Cited by 12
“Some of these include Clostridium, Bifidobacterium, Salmonella, and Streptococcus (Maletzki et al. 2008; Forbes 2010; Zaharuddin et al. 2019).”
BackgroundInfluentialBacterial vectors for active immunotherapy reach clinical and industrial stages
Gouëllec, A. L., Chauchet, X., Polack, B., Buffat, L., & Toussaint, B. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21429 · Cited by 13
Designing a light-activated recombinant alpha hemolysin for colorectal cancer targeting
Alizadeh, S., Barzegari, A., Esmaeili, A., & Omidi, Y. (2019) · Bioimpacts · doi:10.34172/bi.2020.23 · Cited by 15
Editorial on "Cancer and the microbiota" published in Science.
Hamm, A. K., & Weir, T. L. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.07.16 · Cited by 16
“The ability of microbes to target and proliferate within tumor sites opens up new possibilities not only for tumor detection, but delivery of therapeutic drugs (53).”
BackgroundProbiotic-guided CAR-T cells for universal solid tumor targetingPreprint
Vincent, R. L., Gurbatri, C. R., Redenti, A., Coker, C., Arpaia, N., & Danino, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.10.463366 · Cited by 13
Jiang, Y., Zhang, J., Ye, J., Jin, X., Zhao, Y., Xu, H., Chu, B., He, Y., & Wang, H. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01626 · Cited by 12
Zhao, L., Xin, J., Hu, M., Xue, C., & Dong, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.028 · Cited by 19
“In recent years, with the advancement of biomedical technology, the application of bioengineered bacteria in disease treatment has gradually become an active research area [1–3].”
Bacterial Therapy of Cancer: A Way to the Dustbin of History or to the Medicine of the Future?
Ikryannikova, L. N., Gorokhovets, N. V., Belykh, D. A., Kurbatov, L. K., & Zamyatnin, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119726 · Cited by 14
Nanomedicine Disrupts Stromal Barriers to Augment Drug Penetration for Improved Cancer Therapy†
Luo, G., Chen, W., & Zhang, X. (2023) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202300642 · Cited by 12
The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy
Wang, C., Feng, Q., Shi, S., Qin, Y., Lu, H., Zhang, P., Liu, J., & Chen, B. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401538 · Cited by 15
Villanueva, D., Gubieda, A. G., Gandarias, L., Abad, A., Orúe, I., García, J. Á., de Cos, D., Alonso, J. A., & Fdez-Gubieda, M. L. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c13152 · Cited by 12
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Yuan, S., Yang, X., Bremmer, A., Wang, Y., Li, S., Chen, Y., You, Y., & Hu, Q. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507711122 · Cited by 13
“Live bacteria, including EcN, selectively target solid tumors through passive and active mechanisms (41).”
Impacts of the Staphylococcal Enterotoxin H on the Apoptosis and lncRNAs in PC3 and ACHN
Safarpour-Dehkordi, M., Doosti, A., & Jami, M. (2020) · Molecular Genetics Microbiology and Virology · doi:10.3103/s0891416820030076 · Cited by 12
Hu, P., Ly, K. L., Pham, L. P. H., Pottash, A. E., Sheridan, K., Wu, H., Tsao, C., Quan, D. N., Bentley, W. E., Rubloff, G. W., et al. (2022) · Lab on a Chip · doi:10.1039/d2lc00481j · Cited by 13
Bacterial immunotherapy: is it a weapon in our arsenal in the fight against cancer?
Sharma, S., Sharma, H., & Gogoi, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1277677 · Cited by 15
“However, genetic engineering enabled researchers to manipulate the microorganism and knockout/knockdown genes which contributed to reduction of cytotoxic proteins, or virulence factors but enhanced penetration of tumor microenvironment and activate the host ’ s antitumor immune system (31 – 33).”
BackgroundThe engineered Salmonella typhimurium inhibits tumorigenesis in advanced glioma
Wang, W. T., Chen, J., Zhan, Y., Jiang, S., & Li, X. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s86899 · Cited by 12
“typhimurium alone in the SL group.(7,12) ClyA protein can penetrate through the barrier comprised of the host neutrophils that are responsible for keeping Salmonella from spreading.”
BackgroundCombined bacterial and viral treatment: a novel anticancer strategy
Krzykawski, M. P. (2015) · Central European Journal of Immunology · doi:10.5114/ceji.2015.54601 · Cited by 12
Chen, Y., Xie, H., Zou, Y., Lai, X., Ma, L., Liu, Y., & Li, J. (2017) · Molecular BioSystems · doi:10.1039/c7mb00202e · Cited by 12
RetractedEngineered Bacteria with Genetic Circuits Accumulating Nanomagnets as MRI Contrast Agents
Yavuz, M., Ütkür, M., Kehribar, E. Ş., Yağız, E., Sarıtaş, E. Ü., & Şeker, U. Ö. Ş. (2022) · Small · doi:10.1002/smll.202200537 · Cited by 14
Hernández-Luna, M. A., Luría-Pérez, R., & Huerta‐Yépez, S. (2013) · PubMed · Cited by 12
Hsieh, Y.-T., Chen, K., Cheng, C. C., Cheng, T., Tao, M., & Roffler, S. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118028 · Cited by 15
The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009
Zhang, X., Xu, Q., Yang, L., Lai, Y., Zhang, Z., Han, C., Jiang, C., Li, J., Shi, Y., & Hua, Z.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.13217 · Cited by 12
“For example, VNP20009 can specifically target tumors, sense the local environment and respond to external signals and can be engineered at genetic levels [1].”
BackgroundSynthetic engineered bacteria for cancer therapy
Gong, T., & Wu, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2241367 · Cited by 12
Zhang, J., Wang, C., Zhang, Y., Xia, H., Wang, Y., Ma, K., & Wang, J. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109420 · Cited by 14
Genetic engineering of Salmonella spp. for novel vaccine strategies and therapeutics
Bansal, G., Ghanem, M., Sears, K. T., Galen, J. E., & Tennant, S. M. (2024) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0004-2023 · Cited by 16
“The remarkable versatility of Salmonella used as a prophylactic vaccine against infectious diseases has also been investigated in attempts to develop therapeutic interventions against non-infectious diseases such as cancer (109–113).”
Nsingwane, Z., Candy, G. P., Devar, J. W., Omoshoro–Jones, J., Smith, M., & Nweke, E. E. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05648-4 · Cited by 13
Magnet-Targeted Delivery and Imaging
Patrick, P. S., Pankhurst, Q. A., Payne, C., Kalber, T. L., & Lythgoe, M. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-42169-8_6 · Cited by 10
“Recent work indicates a renewed interest in bacterial therapies in general [89], including the use of genetically modified drugsynthesising bacteria [90], and magnetotactic bacteria [91–93].”
BackgroundModulation of oral vaccine efficacy by the gut microbiota
Hou, Y., Li, J., & Wu, Y. (2025) · npj Vaccines · doi:10.1038/s41541-025-01240-8 · Cited by 12
Bacterial chemotaxis to saccharides is governed by a trade-off between sensing and uptake
Norris, N., Alcolombri, U., Keegstra, J. M., Yawata, Y., Menolascina, F., Frazzoli, E., Levine, N. M., Fernandez, V. I., & Stocker, R. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.05.003 · Cited by 13
Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc
Williams, J. S., Higgins, A. T., Stott, K. J., Thomas, C., Farrell, L. E., Bonnet, C. S., Peneva, S., Derrick, A. V., Hay, T., Wang, T., et al. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01206-8 · Cited by 10
“Consequently, it has been possible to harness this bacterium to deliver a range of potential therapeutic payloads to tumour cells [33].”
BackgroundBreaking barriers in cancer treatment: nanobiohybrids empowered by modified bacteria and vesicles
Ijaz, M., Khurshid, M., Gu, J., Hasan, I., Roy, S., Ullah, Z., Liang, S., Cheng, J., Zhang, Y., Mi, C., et al. (2024) · Nanoscale · doi:10.1039/d3nr06666e · Cited by 11
Kato, A., Nomura, S., Takahashi, M., Sukowati, E. W., Harashima, H., & Mukai, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.064 · Cited by 12
Oncolytic bacteria: A revolutionary approach to cancer therapy
Khormi, M. A., Al-Maaqar, S. M., ALjohni, A. R. S., Al-Tayyar, N. A., Alhamad, J. A., Ghyathuddin, A. A. K., Alblawi, Z., Behairy, S. M., Alghamdi, M. A., Alsubhi, W. A., et al. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1076 · Cited by 11
“The tumor tissues that are deoxygenated (anoxic region) promote the aggregation of obligatory anaerobic bacteria in the region [50].”
Wang, Y., Qu, Y., Liu, X., Huang, J. Y., Mao, C., Wang, C., Zhu, S., Zheng, Y., Li, Z., Cui, Z., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.07.004 · Cited by 10
“Consequently, biological strategies aimed at restoring bacterial community homeostasis, such as viable bacterial therapy, have gained traction [16,17].”
Khodavirdipour, A., Nejad, H. R., Zandi, M., Khodavirdipour, A., & Khayyam, N. (2019) · Avicenna Journal of Clinical Microbiology and Infection · doi:10.34172/ajcmi.2019.13 · Cited by 10
Roos, K., Werner, E., & Loessner, H. (2014) · Microbial Biotechnology · doi:10.1111/1751-7915.12187 · Cited by 10
“Moreover, such novel Salmonella vector systems also constitute promising delivery systems for other medical interventions, such as tumour therapy (Forbes, 2010; Leschner and Weiss, 2010).”
BackgroundKazmierczak, R. A., Gentry, B. A., Mumm, T., Schatten, H., & Eisenstark, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160926 · Cited by 10
“The conclusion that Salmonella bacteriotherapy requires additional carried and/or expressed anti-cancer molecules delivered by tumor-infiltrated Salmonella (combination therapy) is a commonly held opinion by prominent researchers in the field of bacteriotherapy [12, 13, 36, 65].”
BackgroundHatefi, A., Karjoo, Z., & Nomani, A. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00739 · Cited by 10
The potential use of theranostic bacteria in cancer
Azizian, K., Pustokhina, I., Ghanavati, R., Hamblin, M. R., Amini, A., & Kouhsari, E. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30152 · Cited by 14
“Studies have shown that live attenuated bacteria can be uses as vectors or vehicles for gene transfer to allow direct expression of tumor suppressor genes, antiangiogenic genes, cytotoxic agents, cytokines, tumor antigens, RNA interference sequences, etc (Forbes, 2010).”
BackgroundInfluentialDevelopment of the quorum sensing biotechnological toolbox
Tsao, C., Quan, D. N., & Bentley, W. E. (2012) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2012.09.008 · Cited by 10
Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy
Qin, S., He, G., & Yang, J. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00741g · Cited by 11
Baghdasaryan, O., Contreras-Llano, L. E., Khan, S. A., Wang, A., Hu, C. J., & Tan, C. (2024) · Nature Protocols · doi:10.1038/s41596-024-01035-6 · Cited by 13
Bismuth-functionalized probiotics for enhanced antitumor radiotherapy and immune activation
Xiao, S., Wang, Y., Pan, S., Mu, M., Chen, B., Li, H., Feng, C., Fan, R., Yu, W., Han, B. R., et al. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00825e · Cited by 9
Engineered Bacterial Production of Volatile Methyl Salicylate
Chien, T., Jones, D. R., & Danino, T. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00497 · Cited by 9
Therapeutic Potential of Clostridium novyi-NT in Cancer: Current Knowledge and Future Perspectives
Sharafabad, B. E., Abdoli, A., Khiav, L. A., Meskini, M., Jamur, P., & Dilmaghani, A. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230413094253 · Cited by 9
Bahuguna, A., & Dubey, S. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188956 · Cited by 11
Recent advances on the application of nanobiomimetic structures as drug delivery systems
Boraei, S. B. A., Javadpour, S., Kamalinejad, F., Otaghvari, F. H., Zare, Y., & Rhee, K. Y. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106009 · Cited by 9
Systematic review on the role of the gut microbiota in tumors and their treatment
Shi, Y., Li, X., & Zhang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1355387 · Cited by 14
The Evolution of Tumor‐Targeted Drug Delivery: From the EPR Effect to Nanoswimmers
Zoaby, N., Golani‐Armon, A., Zinger, A., Reshef, M., Yaari, Z. A., Vardi‐Oknin, D., Shatsberg, Z., Shomar, A., Shainsky‐Roitman, J., & Schroeder, A. (2013) · Israel Journal of Chemistry · doi:10.1002/ijch.201300061 · Cited by 9
Yoo, H., Lee, S., & Cho, D. (2014) · Micromachines · doi:10.3390/mi5041287 · Cited by 9
Shang, W., Tsao, C., Luo, X., Teodoro, M. M., McKay, R., Quan, D. N., Wu, H., Payne, G. F., & Bentley, W. E. (2017) · Biomicrofluidics · doi:10.1063/1.4993438 · Cited by 10
Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer
Schatten, H. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_10 · Cited by 9
Heterologous expression of azurin from Pseudomonas aeruginosa in food-grade Lactococcus lactis
Karaman, M., & Aşkın, H. (2019) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2019.1621894 · Cited by 9
“of peptides and proteins produced by microorganisms in the development of new drugs.([1,2]) Azurin protein of”
BackgroundProspect of bacteria for tumor diagnosis and treatment
Xu, Y., Zhao, C., Ma, X., & Zhang, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121215 · Cited by 9
Wei, Y., Zhang, Z., Xue, T., Lin, Z., Chen, X., Tian, Y., Li, Y., Jing, Z., Fang, W., Fang, T., et al. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00569 · Cited by 9
Nowicka, A., Tomczak, H., Szałek, E., Karbownik, A., & Gil, L. (2025) · Biomedicines · doi:10.3390/biomedicines13071761 · Cited by 9
“…the targeted delivery of anticancer agents; (3) the bacterial expression of tumor-specific antigens; (4) the delivery or expression of suppressor genes, anti-angiogenic genes, and suicide genes; (5) RNA interference mechanisms; and (6) the activation of pro-drugs through bacterial cleavage [155].”
Current advances in microbial-based cancer therapies
Shahbaz, A., Mahmood, T., Javed, M. U., & Abbasi, B. H. (2023) · Medical Oncology · doi:10.1007/s12032-023-02074-x · Cited by 9
“tissue necrosis, which is the death of tumor cells as a result of nutrition deprivation and unchecked growth [72].”
BackgroundEnhanced anti-cancer efficacy of arginine deaminase expressed by tumor-seeking Salmonella Gallinarum
Duysak, T., Kim, K., Yun, M., Jeong, J., & Choy, H. E. (2024) · Oncogene · doi:10.1038/s41388-024-03176-0 · Cited by 9
“In its early stages, clinicians employed live bacteria, such as Streptococci and Clostridia , for cancer treatment [1 – 5].”
Lucıanı, L., Dubourg, G., Graillon, T., Honnorat, E., Lépidi, H., Drancourt, M., Seng, P., & Stein, A. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-0973-9 · Cited by 8
“These phenomena might be explained by Salmonella’s tropism for necrotic tissue [23], and the central nervous system infection could be secondary to blood dissemination of Salmonella from digestive reservoirs in the bile or intestine.”
BackgroundSchultz, M., & Burton, J. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804024-9.00005-7 · Cited by 12
Chaturvedi, R., Kang, Y., Eom, Y., Torati, S. R., & Kim, C. (2021) · Biology · doi:10.3390/biology10100993 · Cited by 8
“Moreover, such an approach has been already shown to work properly in the hypoxic regions of tumors [20].”
BackgroundApplication of Bacterial Whole-Cell Biosensors in Health
Song, Y., Rampley, C. P. N., Chen, X., Du, F., Thompson, I. P., & Huang, W. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-23217-7_136 · Cited by 10
Constitutive Expression of a Cytotoxic Anticancer Protein in Tumor-Colonizing Bacteria
Mai, P.-T., Lim, D., So, E., Kim, H.-Y., Duysak, T., Tran, T.-Q., Song, M., Jeong, J., & Choy, H. E. (2023) · Cancers · doi:10.3390/cancers15051486 · Cited by 10
Synthetic Biology & Bioinformatics Prospects in the Cancer Arena
Rodrigues, L. R., & Leon, D. (2011) · InTech eBooks · doi:10.5772/21505 · Cited by 9
“butyricum M-55 has been tested for squamous cell carcinoma, metastic, malignant neuroma and melanoma) have been carried out (Forbes, 2010).”
BackgroundInfluentialMathematical Ecology of Cancer
Hillen, T., & Lewis, M. A. (2014) · Springer proceedings in mathematics & statistics · doi:10.1007/978-3-319-03759-2_1 · Cited by 8
Salmonella enterica: un aliado en la terapia contra el cáncer
Chávez-Navarro, H., Hernández-Cueto, D., Vilchis-Estrada, A., Bermúdez-Pulido, D. C., Antonio-Andrés, G., & Luría-Pérez, R. (2015) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2015.02.005 · Cited by 8
Bactofection of sequences encoding a Bax protein peptide chemosensitizes prostate cancer tumor cells
Hernández-Luna, M. A., de León-Ortega, R. D., Hernández-Cueto, D., Gaxiola-Centeno, R., Castro-Luna, R., Martínez-Cristóbal, L., Huerta‐Yépez, S., & Luría-Pérez, R. (2016) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2016.10.002 · Cited by 8
“The use of live-attenuated bacterial vectors has been proposed to solve these problems since they can migrate into the tumor microenvironment and become true protein, peptide and nucleotide sequence factories once localized within the tumor.(12) One of the live-attenuated bacterial vectors used for this purpose is Sal…”
BackgroundTowards cell-based therapeutics: A bio-inspired autonomous drug delivery system
Lo, C., Bhardwaj, K., & Mărculescu, R. (2017) · Nano Communication Networks · doi:10.1016/j.nancom.2017.01.006 · Cited by 8
“To address both problems, targeted cellbased therapies have gained significant attention recently [4].”
BackgroundLee, K. R., Wakeel, A., Chakraborty, P., Foote, C. S., Kajiura, L. N., Barrozo, J. C., Chan, A. C., Bazarov, A. V., Spitler, R., Kutny, P. M., et al. (2017) · Molecular Imaging and Biology · doi:10.1007/s11307-017-1094-6 · Cited by 7
Salmonella -Mediated Cytolethal Distending Toxin Transfer Inhibits Tumor Growth
Wang, W.-K., Chiang, W.-C., Lai, C., & Lee, C. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.030 · Cited by 8
Photocatalytic scaffolds enhance anticancer performances of bacterial consortium AUN
Miyahara, M., Doi, Y., Takaya, N., & Miyako, E. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.156378 · Cited by 8
Bacterial-Mediated In Situ Engineering of Tumour-Associated Macrophages for Cancer Immunotherapy
Kuhl, G. C., & Tangney, M. (2025) · Cancers · doi:10.3390/cancers17050723 · Cited by 9
“To mitigate these risks, rigorous safety assessments, including preclinical studies and controlled clinical trials, are essential [195].”
Engineered nano-bacteria hybrids for precision cancer immunotherapy
Yu, L., Qiu, Y., Li, R., Xu, Z. C., & Li, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102484 · Cited by 10
“Bacteria exhibit unique advantages in tumor immunotherapy due to their natural tropism for the hypoxic tumor microenvironment, intrinsic immunogenicity, and genetic plasticity, making them ideal living drug delivery systems [29].”
Engineered Bacterial Biomaterials for Augmenting Adoptive Immune Cell Therapy Against Solid Tumors
Zhu, C., Sun, Z., Wu, Q., Wang, F., Zhang, L. L., Wang, W., Ding, Y., & Li, H. (2026) · Advanced Materials · doi:10.1002/adma.202522140 · Cited by 11
Engineering Escherichia coli Nissle 1917 to scavenge lactate enhances anti-tumor immunity
Li, X., Wang, Y., Xie, H., Sun, C., Chen, J., Zhang, B., Wang, W., & Gu, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114738 · Cited by 8
Imaging Tumor-Targeting Bacteria Using 18F-Fluorodeoxysorbitol Positron Emission Tomography
Ordoñez, A. A., Saupe, F., Kasper, C. A., Turner, M. L., Parveen, S., Flavahan, K., Shin, H., Artemov, D., Ittig, S., & Jain, S. K. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad077 · Cited by 6
Danielson, M., Nicolai, C. J., Vo, T. T., Wolf, N. K., & Burke, T. (2024) · iScience · doi:10.1016/j.isci.2024.111385 · Cited by 9
Yin, Y., Cheng, X. L., Xie, R., Fan, D., Li, H., Zhong, S., Wegner, S. V., Zeng, W., & Chen, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113787 · Cited by 9
Hunting field: insights on distribution pattern of bacteria and immune cells in solid tumors
Li, Y., Wang, Y., Li, X., & Liu, C. (2021) · National Science Review · doi:10.1093/nsr/nwab023 · Cited by 7
Chong, A., Nguyen, D.-H., Kim, H. S., Chung, J., & Min, J. (2022) · Molecular Imaging · doi:10.1155/2022/9222331 · Cited by 10
Bimodal Imaging of Tumors via Genetically Engineered Escherichia coli
Zhang, L., Wang, Y., Li, D., Wang, L., Li, Z., & Yan, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091804 · Cited by 9
“coli MG1655 can effectively colonize and self-replicate in solid tumors [2,7,20].”
BackgroundHamilton, S., Shea, D., Ibsen, S. D., & Brasino, M. D. (2022) · Electrophoresis · doi:10.1002/elps.202200214 · Cited by 8
“Building on this research, there have been many attempts to rationally modify bacteria to enhance their therapeutic properties [10].”
BackgroundAccumulation of single-stranded DNA in Escherichia coli carrying the colicin plasmid pColE3-CA38
Morales, M., Attai, H., Troy, K., & Bermudes, D. G. (2014) · Plasmid · doi:10.1016/j.plasmid.2014.11.001 · Cited by 7
“Several bacterial strains with tumor-targeting capability including Salmonella sp. are currently being investigated for their potential use in cancer therapeutics (Forbes, 2010; Hoffman and Zhao, 2014; Low et al., 1999; Pawelek et al., 1997).”
Development of bacterial nitroreductase enzymes for noninvasive imaging in cancer gene therapy
Williams, E. M. (2013) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17014019 · Cited by 10
Hababag, E. A. C., Cauilan, A., Quintero, D. A., & Bermudes, D. G. (2023) · Microorganisms · doi:10.3390/microorganisms11051355 · Cited by 6
Advances in engineered bacteria for cancer therapy
Pan, W., Liu, H., & Wu, D. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100017 · Cited by 6
Live bacterial chemistry in biomedicine
Zhao, S., Chen, Q., Saiding, Q., An, S., Zhou, Z., Kong, N., Heng, Y. J., Abdi, R., & Tao, W. (2025) · Chem · doi:10.1016/j.chempr.2025.102436 · Cited by 9
Yang, M., Yang, M., Li, J., Bai, L., Cheng, Y., Liu, Y., Cao, M., Yang, X., Wang, Y., & Liu, Y. (2025) · Advanced Science · doi:10.1002/advs.202505310 · Cited by 9
Engineered Lactiplantibacillus plantarum WCFS1 as a Biosensor Probe for Lung Cancer
Brasino, M. D., Wagnell, E., Manalo, E. C., Drennan, S. L., Fischer, J. M., & Merritt, J. L. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.5c00186 · Cited by 7
Metadata
- Authors
- Forbes, N. S.
- Affiliations
- University of Massachusetts Amherst (US)
- Corresponding author
- Forbes, Neil S.
- ORCID
- Forbes, Neil S.
- Venue
- Nature Reviews Cancer
- Published
- 2010-10-14
- Volume
- 10
- Issue
- 11
- Pages
- 785-794
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3756932
- OpenAlex
- W1979507175
- Cited by
- 905
- References
- 141
- Citations by year
- 2026: 76 · 2025: 89 · 2024: 95 · 2023: 76 · 2022: 81 · 2021: 81 · 2020: 69 · 2019: 47 · 2018: 47 · 2017: 46 · 2016: 42 · 2015: 40 · 2014: 45 · 2013: 37 · 2012: 20
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA120825, CA120825)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- bacterial cancer therapy, synthetic biology, Salmonella, Clostridium, tumor targeting, bacterial cytotoxicity, bacterial stability, bacterial toxicity, tumor growth control, cancer immunotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Clostridium, Genetic Engineering, Humans, Neoplasms, Salmonella
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.